PPD Named Best Contract Research Organization and Honored for Best Technological Development in Clinical Trials by Scrip
November 04 2011 - 09:30AM
Business Wire
Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today
announced it has been named the best contract research organization
by Scrip Intelligence, which also has honored PPD for deploying the
best technological development in clinical trials.
Scrip presented both awards to PPD at the seventh annual Scrip
Awards ceremony on November 3 in London. PPD was recognized for its
expertise and innovation in helping clients develop life-changing
medical treatments. The judging panel called PPD “a great
organization – open for new approaches, even more for driving new
technologies.”
“At PPD, we share our clients’ passion for delivering new
therapies to help people live healthier lives,” said Raymond Hill,
chief executive officer of PPD. “These awards pay testament to the
hard work, dedication and inspiration that our employees deliver
every day to provide exceptional client service. We are committed
to delivering consistent high quality, innovative ideas and
forward-focused technologies that help our clients achieve their
vision.”
Launched in 1985 as a one-person consulting firm, today PPD is
one of the world’s leading contract research organizations. PPD has
worked with 49 of the top 50 pharmaceutical companies to speed the
delivery of life-changing therapies to people in need.
Scrip also recognized PPD’s innovative technology solution,
created in collaboration with Microsoft Corp., that improves the
efficiency of managing Risk Evaluation and Mitigation Strategy
(REMS) programs mandated by the U.S. Food and Drug Administration.
Designed to improve patient safety, REMS programs help ensure the
safe distribution and administration of certain marketed drugs.
The PPD REMS solution is a first-of-its-kind technology platform
that integrates, manages and tracks all REMS resources, data and
information. It is based on the Microsoft Amalga Unified
Intelligence System, a data aggregation platform that gives
healthcare professionals access to the information they need when
they need it, and Microsoft HealthVault, a personal health
application platform that lets consumers gather, store and share
health information online.
“PPD’s technology focus is to deliver solutions that provide
meaningful advances for our clients,” said Mike Wilkinson,
executive vice president and chief information officer of PPD. “Our
REMS solution builds on PPD’s extensive strategic, scientific,
operational and regulatory capabilities in designing and
implementing comprehensive REMS and risk management programs.”
The Scrip Awards acknowledge achievements across a broad range
of areas in the pharmaceutical industry. Attracting hundreds of
industry professionals from the world’s leading pharmaceutical and
biotechnology companies, the awards have become a distinct mark of
superior achievement. Pharmaceutical, biotech and contract research
organizations compete for awards in 15 categories, which are
decided by an expert panel of judges.
Scrip’s recognition is the most recent in a series of awards PPD
has received this year. PPD earned the number one spot among
contract research organizations in the 2011 CenterWatch global site
survey. PPD also was named to the 2011 InformationWeek 500, an
annual list of the most innovative users of business technology in
the United States. In addition, PPD and ProtonMedia won a Microsoft
2011 Life Sciences Innovation Award for PPD® 3D, a virtual,
collaborative environment improving the cost-effectiveness, speed
and quality of training for clinical research associates.
About PPD
PPD is a leading global contract research organization providing
drug discovery, development and lifecycle management services. Our
clients and partners include pharmaceutical, biotechnology, medical
device, academic and government organizations. With offices in 44
countries and more than 11,000 professionals worldwide, PPD applies
innovative technologies, therapeutic expertise and a commitment to
quality to help clients and partners accelerate the delivery of
safe and effective therapeutics and maximize the returns on their
R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements,
expectations and assumptions, including statements, expectations
and assumptions about PPD in relation to the Scrip Awards,
contained in this news release are forward-looking statements that
involve a number of risks and uncertainties. Although PPD attempts
to be accurate in making these forward-looking statements, it is
possible that future circumstances might differ from the
assumptions on which such statements are based and could cause
actual results to differ materially from the forward-looking
statements. Other important factors which could cause future
results to differ materially include the following: overall global
economic conditions; economic conditions, research and development
spending, and outsourcing trends in the pharmaceutical,
biotechnology and government-sponsored research sectors;
consolidation in the pharmaceutical and biotechnology industries;
competition in the outsourcing industry; PPD’s ability to win new
business; loss, delay or modification of large contracts;
higher-than-expected cancellation rates; the rate of conversion of
backlog into revenue; actual operating performance; fluctuations in
currency exchange rates; the ability to attract, integrate and
retain key personnel; risks associated with and dependence on
strategic relationships; risks associated with acquisitions and
investments, such as impairments and integration, including PPD’s
investment in Celtic Therapeutics; rapid technological advances
that make our services less competitive; risks associated with
fixed price contracts and cost overruns; compliance with drug
development regulations; changes in the regulation of the drug
development process; international economic and political risks;
risks that we may increase, reduce or discontinue our annual
dividend policy; and the ability to control SG&A spending.
These and other PPD risk factors are set forth in more detail from
time to time in our SEC filings, copies of which are available free
of charge upon request from PPD’s investor relations department.
PPD assumes no obligation and expressly disclaims any duty to
update these forward-looking statements in the future, except as
required by applicable law. These forward-looking statements should
not be relied upon as representing PPD’s estimates or views as of
any date subsequent to the date hereof.
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Mar 2023 to Mar 2024